Veradermics, Inc (MANE) stock
MANENYSEPharmaceutical PreparationsFiscal year ends December 31
$124.86−0.78 (-0.62%)
Close on Nov 18, 2026Market cap $5.22BP/E –Yield –
Veradermics net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2025 it was -$70.00M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$70.00M | – |
| FY2024 | Dec 31, 2024 | -$26.49M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$23.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.23M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.40M | – |
See a number that looks wrong?